Back to search

Article

Real-World Outcomes and Clinical Heterogeneity of First-Line Immunochemotherapy in Extensive-Stage Small-Cell Lung Cancer

2026-06-10

Abstract excerpt

<title>Abstract</title> <p>Background Although first-line immunochemotherapy has become a standard treatment for extensive-stage small-cell lung cancer (ES-SCLC), the generalizability of clinical trial findings to heterogeneous real-world populations remains limited. We conducted a retrospective cohort study to to evaluate its effectiveness and safety in routine practice. Methods We retrospectively analyzed dat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5dfb7a72-9cf4-501c-a2ca-d9b551ed0fb4
DOI
10.21203/rs.3.rs-9699215/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Real-World Outcomes and Clinical Heterogeneity of First-Line Immunochemotherapy in Extensive-Stage Small-Cell Lung CancerDOI 10.21203/rs.3.rs-9699215/v1
Efficacy and Safety of Immuno-based Therapy Versus Standard of Care in Extensive-stage Small-Cell Lung Cancer: An Updated Meta-analysis of Randomized Clinical TrialsSemantic proximity
Comparison of efficacy and safety between PD-1 inhibitors and PD- L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysisSemantic proximity
Comparative Safety of Immune Checkpoint Inhibitors and Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-AnalysisSemantic proximity
Efficacy and safety of immune checkpoint inhibitors versus chemotherapy in advanced non-small cell lung cancer: A systematic review of randomized controlled trialsSemantic proximity
Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study.Semantic proximity
Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis.Semantic proximity
Characteristics and Hematological Indicators Predictors of Immunotherapy Response in Advanced Non-Small Cell Lung CancerSemantic proximity
Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival OutcomesSemantic proximity
Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations.Semantic proximity
Oncological therapy in stage IV lung cancer patients at the end-of-life – A retrospective single-center cohort analysis in the era of tyrosine kinase inhibition and immunotherapySemantic proximity
Retrospective Analysis of Real-World Treatment Patterns and Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Starting First-Line Systemic Therapy in the United KingdomSemantic proximity
Real-world Data Analysis of Immunotherapy in Advanced Lung CancerSemantic proximity
Select a neighboring publication to make it the new centre.